The effect of intrauterine administration of estradiol on postpartum uterine involution in cattle.
In cattle, the first postpartum dominant follicle has a predilection for the ovary contralateral to the previously gravid uterine horn. However, the presence of an estradiol-secreting dominant follicle in the ipsilateral ovary is a marker of subsequent fertility, possibly due to a localized effect of ovarian estradiol on uterine involution. The present study tested the hypothesis that estradiol increases the rate of uterine involution when administered into the previously gravid uterine horn around the expected time of selection of the first postpartum dominant follicle. Dairy cows were treated with 10 mg estradiol benzoate (n=15) or saline (n=14) administered through the cervix into the previously gravid uterine horn lumen on Days 7 and 10 postpartum. Uterine involution was monitored by daily transrectal ultrasonography and estimation of peripheral plasma concentrations of PGFM and acute phase proteins, while ovarian function was monitored by ultrasonography and measurement of plasma hormone concentrations. There was no effect of estradiol treatment on the diameter of the previously gravid or nongravid uterine horns, nor on the plasma concentrations of PGFM or acute phase proteins. However, cows in which the first postpartum dominant follicle ovulated during the study period had a smaller diameter of the previously gravid (P<0.01) or nongravid uterine horns (P<0.001) compared with cows in which the follicle regressed. Thus, our hypothesis was not proven, and the opposite pathway of utero-ovarian signaling may be more important during the postpartum period.
Sheldon
I Martin
IM
Department of Veterinary Clinical Science, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts AL9 7TA, UK. msheldon@rvc.ac.uk
Noakes
David E
DE
Rycroft
Andrew N
AN
Dobson
Hilary
H
D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000502:physiology*; D002570:Ceruloplasmin / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006242:Haptoglobins / Q000378:metabolism; D009961:Orosomucoid / Q000378:metabolism; D006080:Ovarian Follicle / Q000000981:diagnostic imaging / Q000502:physiology; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D014463:Ultrasonography; D014599:Uterus / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology
D006242:Haptoglobins; D009961:Orosomucoid; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D015237:Dinoprost; D002570:Ceruloplasmin